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1 year 3 years 5 years
Group 1 91%(4) 86%(5) 83%(6)
Group 2 86%(9) 86%(9) 86%(9)
Group 3 87%(9) 73%(12) 73%(12)
Group 4 63%(11) 46%(12) 38%(12)
Year Total # of units destroyed
2011 112
2012 35
2013* 127
*Through 10/9/2013
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chemotherapy (CT) we divided the pt in the following
groups: 1) 64 pt in 1st complete remission (CR) after 1 CT
line, all with IPI2; 2) 15 pt in 1st CR after 2 CT lines; 3) 15
pt in 2nd CR; 4) 19 pt with more advanced diseased. Ritux-
imab (R) was used with CT in 78 pt before SCT. The 1st line
CT most frequently used was: R-CHOP: 71 pt (63%); CHOP:
28 pt (25%).
Conditioning regimen was: 93 pt BEAM and 20 pt
FEAM. Hematopoietic stem cells were collected from:
peripheral blood (PB) in 100, bone marrow (BM) in 2, and
PB+BM in 11 pt.
The cause of death was: relapse/progression - 17 pt; non-
relapsed mortality e 8 pt and secondary neoplasia 1pt.
The median follow up of alive pt was 34 months (1-221).
Overall survival (OS) at 1, 3 and 5 years was 85%(3);
75%(4); 73%(5). DFS at 1, 3 and 5 years was 84%(4);
80%(4); 75%(5) respectively.
There were signiﬁcant differences in OS between the 4
groups considered e table 2 (p<0.01). In univariate anal-
ysis OS was signiﬁcantly better if: early stage at diagnosis,
less than 2 CT lines before SCT, disease status before SCT in
CR, ﬁrst line CT with R-CHOP, PB stem cells.
Conclusion: About 70 % of high-risk pt were free of disease
after conventional CT followed by SCT. The outcome is
inﬂuenced by disease status at SCT. Despite our results don’t
allow direct comparison of the impact of immunoCT with R,
our pt in the R group had a better outcome.Most studies with
SCT consolidation in these pt were performed in the pre-R
era. There is as need to redeﬁne the role of this treatment
strategy nowadays. Further knowledge of prognosis factors is
necessary, especially in young pt with high-risk disease at 1st
CR, to determine whether the SCT still improves outcome.BMT ADMINISTRATORS/QUALITY157
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Background/Objective: 126 patients were identiﬁed as be-
ing deceased with over 350 stem cell units in storage. The
inability to dispose of these cells has a signiﬁcant impact on
our program; primarily freezer space availability.
The process of obtaining required documentation for the
disposal of cells had not been streamlined, and no one had
oversight for the process, resulting in a lack of documenta-
tion needed to dispose of cells.
Methods: In June of 2012, a data manager took ownership of
the project. In July of 2012, the Cellular Therapeutics
Department Cell Destruction Policy was revised to include
the SSDI report as valid documentation necessary for
destruction of cells and the new process was implemented.Per programmatic policy, appropriate documentation is
requested as soon as possible after notiﬁcation of a re-
cipient’s death. Aggressive attempts are made to obtain
EITHER:
A death certiﬁcate
OR An SSDI report
If any information is inconsistent, additional corrobo-
rating documentation is still necessary to corroborate patient
identiﬁcation. These documents are scanned and stored on a
(secure) shared drive.
The Cellular Therapeutics (CT) Team then reviews docu-
mentation submitted by the data management team.
Appropriate forms are ﬁlled out by CT and the documenta-
tion is veriﬁed by a second CT Team member. Forms must
then be signed by either the Processing Facility Medical Di-
rector or the recipient’s physician per FACT Guidelines (D
11.1.4). The Product disposal may then occur per policy.
Results: Our freezer capacity is 3660 total units (11 freezers
of different sizes). 2627 Autologous Units and 705 Allogeneic
Units ¼ 3332 total units are currently stored (10/1/
13). With ownership of the new streamlined process,
documentation has been received on an additional 52 pa-
tients (150 units) are now eligible for destruction, and
documentation is pending on an additional 37 patients (104
units). 2013 data represents a 72% increase in cells eligible for
destruction over 2012.158
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Abstract/Background: The prevention of hospital acquired
infections is an ongoing performance improvement oppor-
tunity in our hematopoietic stem cell transplant (HSCT)
population. An outbreak of Vancomycin-Resistant Entero-
cocci (VRE) occurred in late 2011 that extended through
2012. A multidisciplinary approach to impact VRE has
resulted in major improvement and sustained reduction in
VRE rates in 2013.
Objective/Methods:
1. Multidisciplinary Integration
In order to achieve the goal of preventing Hospital
Acquired Infections our program works closely with
the hospital Infection Prevention (IP) team. The IP
team attends/reports unit data and opportunities to:
HSCT Quality Management Meeting (ad hoc)
 Sarah Cannon Blood Cancer Network Infection Pre-
vention Team and Quality Calls
 Both the HSCT and the IP team participate in
monthly IP Multidisciplinary Rounding
 IP performs consultative review of IP speciﬁc HSCT
Policies and Procedures
